Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00768755 · ClinicalTrials.gov registry record · Phase 1

Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer

A Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
180
Enrollment target
20
Study locations

NCT00768755 is a Phase 1 study of Carcinoma, Non-Small Cell Lung that has completed, run by Pfizer. The registered enrollment target is 180 participants, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00768755, a Phase 1 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
180 participants
Enrollment target
20
Study locations

Study Summary

AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC).

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG axitinib
  • DRUG chemotherapy

Study Locations (20)

Other

  • Pfizer Investigational Site - Genova
  • Pfizer Investigational Site - Lido Di Camaiore (LU)
  • Pfizer Investigational Site - Orbassano (TO)
  • Pfizer Investigational Site - Lubin
  • Pfizer Investigational Site - Otwock
  • Pfizer Investigational Site - Piła
  • Pfizer Investigational Site - Poznan

Georgia

  • Pfizer Investigational Site - Atlanta
  • Pfizer Investigational Site - Decatur
  • Pfizer Investigational Site - Macon
  • Pfizer Investigational Site - Marietta
  • Pfizer Investigational Site - Sandy Springs

Illinois

  • Pfizer Investigational Site - Bloomington
  • Pfizer Investigational Site - Peoria

Pennsylvania

  • Pfizer Investigational Site - Hershey
  • Pfizer Investigational Site - West Reading

Rhode Island

  • Pfizer Investigational Site - East Providence
  • Pfizer Investigational Site - East Providence

Alabama

  • Pfizer Investigational Site - Huntsville

Shizuoka

  • Pfizer Investigational Site - Sunto-gun

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2009-01
Est. Completion 2012-03
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00768755

The ClinicalTrials.gov registry entry for NCT00768755 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (44% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which axitinib is the first listed.

NCT00768755 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Georgia, Illinois.

Frequently Asked Questions

What is clinical trial NCT00768755 about?

NCT00768755 is a clinical study titled "Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer". AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC).

What is the current status of trial NCT00768755?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2009-01. Estimated completion is 2012-03.

What conditions does trial NCT00768755 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT00768755?

The interventions under investigation include: axitinib (DRUG), chemotherapy (DRUG).

Who is sponsoring clinical trial NCT00768755?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00768755 being conducted?

This trial has 20 study locations across Alabama, Georgia, Illinois, Pennsylvania, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.